Corneo-Uveal-Retinal Adverse Effects after Single Course of Targeted Anti-Cancer Therapy: Case Report and Review of Literature

Abstract

Oral anti vascular endothelial growth factors therapeutic agents have been evolving rapidly over the last past decades and became one of the great contributors to advancement of cancer therapy and increasing survival rate of the treated patients.Sorafenib is FDA approved medications for the treatment of solid tumors.In this article, we reported the clinical features of the first Saudi patient presenting with corneo-uveal retinal adverse effects with subsequent bilateral irreversible blindness.